Inhibitors of soluble epoxide hydrolase and p38 kinase as Alzheimer's therapeutics

Case ID: 19/0025

Description

A Potent Neuroprotective Mechanism for Alzheimer’s Disease

 

 

 

Case ID:

18/0025

 

Background

Alzheimer’s disease (AD) is the most common neurodegenerative disorder. Neuroinflammation is a prevalent pathogenic stress leading to neuronal death in AD. Targeting neuroinflammation to keep neurons alive is an attractive strategy for AD therapy. 1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU) is a potent and blood-brain barrier permeable inhibitor of soluble epoxide hydrolase (sEH). It has a good efficacy on a wide range of chronic inflammatory diseases in preclinical animal models. However, the anti-neuroinflammatory effects and molecular mechanisms of TPPU for potential AD interventions remain elusive.

 

Technology Overview

Researchers at the University of Hawaii’s Molecular Biosciences and Bioengineering Department have developed a novel method using TPPU to treat AD.

TPPU selectively inhibits both sEH and p38β kinase, showing a neuropharmacology in multiple AD signaling pathways. TPPU effectively prevents neuronal death by mitigating amyloid toxicity, tau hyperphosphorylation and mitochondrial dysfunction in the human neuron SH-SY5Y cells, and promoting neurite outgrowth and suppressing activation and nuclear translocation of NF-κB for inflammatory responses.

 

Features

TPPU selectively inhibits soluble epoxide hydrolase (sEHs);

TPPU selectively inhibits p38 kinase;

TPPU protects neurite outgrowth against Aβ42 neurotoxicity;

TPPU and epoxyeicosatrienoic acids (EETs) prevent Aβ-induced cytotoxicity in SH-SY5Y cells;

TPPU attenuates tau hyperphosphorylation induced by Aβ42 in human SH-SY5Y cells;

TPPU and EETs prevent Aβ-induced depolarization of mitochondrial membrane potential and mitochondrial dysfunction; and

TPPU suppresses activation and nuclear translocation of the transcription factor NF-κB in differentiated SH-SY5Y cells.

 

Potential Benefits

TPPU is a potential disease-modifying therapy for AD.

 

IP Status

Utility patent application filed

 

Seeking

Development partner

Commercial partner

Licensing

University spin out

Investment

 

Key Words

1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea

AD signaling pathways

Alzheimer’s disease;

p38 MAPK

p38 mitogen-activated protein kinase

TPPU

 

Patent Information:
Inventors
Qing Xiao Li
Zhibin (Ben) Liang

For information, contact:
Rafael Gacel-Sinclair
Technology Licensing Associate
University of Hawaii
gacel@hawaii.edu
Keywords


Categories
Therapeutic
Healthcare
© 2019. All Rights Reserved. Powered by Inteum